World Changing. Life Saving. For Good.

NTx was founded for global health, with a mission to improve tuberculosis treatments while reducing the cost and increasing access. That original mission propelled our team to pursue a new methodology, “in vitro synthetic biology,” to improve production speed, quality, and cost for difficult-to-make compounds that address a wide range of diseases.

NTx first developed NTxpress^®, a recombinant protein continuous flow platform. As the COVID-19 pandemic unfolded, we recognized the value of a continuous flow system and enhanced our initial platform by introducing a second one, NTxscribe^®, designed to create mRNA-based products through transcription, the initial phase of protein translation.